(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average b	ourden						
hours per response	0.5						

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Colowick Alan				THR [TH	Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD] Date of Earliest Transaction (Month/Day/Year)							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) Chief Medical Officer				
	RESHOLD	PHARMACEU ORT BLVD., 5TH	· · · · · · · · · · · · · · · · · · ·	3. Da 03/1			ansac	ction (Mo	nth/Day/	Year)						
(Street) REDWOOD CITY, CA 94063			4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Cit	ty)	(State)	(Zip)				Tal	ble I - No	n-Deriv	ative Securities	Acquire	ed, Disposed o	f, or Benefic	cially Owned		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yes		ear) Ex	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		(A)	4. Securities Acquire (A) or Disposed of (I (Instr. 3, 4 and 5) (A) or				C F C	wnership orm: Be irect (D) Indirect (I	eneficial wnership		
							(Code	V Am		Price			×	nstr. 4)	
		•		II - Der (<i>e</i> .g.	ivati	ve Securiti ts, calls, wa	ies A	Pe thi cu cquired, nts, option	rsons v s form rrently Dispose	who respond are not requi valid OMB co d of, or Benefic ertible securiti	red to re ontrol nu cially Ov es)	espond unle ımber. [,] ned	ss the form	i displays a		74 (9-02)
Security	Conversion	3. Transaction Date (Month/Day/Year)		Code	ransaction ode Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Date Exercisable		on Date Day/Yea	Date y/Year) Expiration		7. Title and Amount of Underlying Securities (Instr. 3 and 4) Title Amount or Number of Shares		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
Stock Option (Right to Buy)	\$ 14.51	03/14/2006		A	V	(A) 150,000	()	02/01/2	2006 ⁽²⁾	03/13/2016	Comn	non 150.000		150,000	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Colowick Alan C/O THRESHOLD PHARMACEUTICALS, INC. 1300 SEAPORT BLVD., 5TH FLOOR REDWOOD CITY, CA 94063			Chief Medical Officer				

Signatures

/s/ David Southern, Attorney-in-Fact	03/15/2006
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option was granted pursuant to the Threshold Pharmaceuticals, Inc. 2004 Amended and Restated Equity Incentive Plan.
- (2) The option shall vest and become exercisable at the rate of 1/48 of the shares subject to the option on February 1, 2006 and 1/48 of the shares subject to the option on each monthly anniversary following February 1, 2006.

(3) Not Applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.